2025 年 3 月 25 日清华大学药学院丁胜教授团队在 Immunity 期刊发表文章揭示了Mef2C作为小胶质细胞检查点的具体分子机制，并进一步发现CDK2抑制剂BMS ...

为探究 MEF2C 调节小胶质细胞激活机制，研究人员开展相关研究，发现该通路及 CDK2 抑制剂作用，意义重大。 小胶质细胞内在免疫检查点是维持免疫稳态的重要保障，能防止小胶质细胞过度激活，这一过程对自闭症谱系障碍（ASD）等神经系统疾病影响显著。

"These striking new findings validate the combination of INX-315 with CDK4/6 inhibitors as a promising therapeutic strategy with potential application beyond patients with CDK2-addicted cancers ...

NiKang Therapeutics has concluded the first cohort dosing in the open-label Phase I trial of NKT3964 as a monotherapy for treating adults with advanced or metastatic solid tumours. The dose-escalation ...